Shares of Hoth Therapeutics, Inc. (HOTH) are surging over 50% on Wednesday after the biopharmaceutical company said it has signed a production deal for cancer treatment.
HOTH is currently trading at $2.48, up $0.84 or 51.22%, on the Nasdaq.
Hoth Therapeutics announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment drug, HT-001.
Recently, Hoth requested a Pre-Investigational New Drug meeting to the FDA to discuss a proposed drug development program for the novel treatment.
HT-001 is a topical formulation designed for the treatment of patients with mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor inhibitor therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.